DRKS00010112
Completed
Not Applicable
on-interventional trial on the postoperative use of bromelain tablets hysan in an ENT setting - BROHNO-2015
RSAPHARM Arzneimittel GmbH0 sites102 target enrollmentMarch 1, 2016
Conditionssurgeries in ENT, not prespecified
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- surgeries in ENT, not prespecified
- Sponsor
- RSAPHARM Arzneimittel GmbH
- Enrollment
- 102
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients \= 12 Jahre
- •\- Surgery in ENT setting
- •\- doctor's decision to prescribe bromelain tablets hysan is Independent from decistion to include the Patient into the study
Exclusion Criteria
- •Due to the non\-interventional character of the study, no exclusion criteria are predefined.
- •Contraindications and interactions as described in SPC must be considered.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
An audit of fluid treatment during surgeries in preplanned surgeriesHealth Condition 1: C00-D49- NeoplasmsCTRI/2022/08/044946Tata Memorial Hospital
Recruiting
Phase 3
on-randimized confirmatory trial of postoperative concurrent chemoradiotherapy (CCRT) using IMRT for patients with high-risk uterine cervical cancer (JCOG1402, PopCC IMRT-CCRT)Postoperative uterine cervical cancer patients with high-risk prognostic factorsJPRN-UMIN000027017Japan Clinical Oncology Group (JCOG)220
Active, not recruiting
Phase 1
A trial comparing chemotherapy and bevacizumab or lapatinib with chemotherapy alone for cancer of the stomach, oesophagus or the junction of the stomach and oesophagusPatients with histologically verfied lower oesophageal, Siewert Type I, II or III oesophagogastric junction or gastric adenocarcinoma.Type III or gastric tumours should be stage 1b (T1N1, T2a/bN0), II,III or stage IV (T4 N1orN2 M0). Lower oesophageal, Type I and II tumours should be stage II to stage IVa (T1N1, T2N1, T3N0-1, but not T2N0). T4 tumours are eligible if they involve the crura or invade the mediatinal pleural only.The tumour should be operableMedDRA version: 18.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2006-000811-12-GBMedical Research Council Clinical Trials Unit1,100
Recruiting
Phase 4
Prospective-randomized trial on the postoperative outcome after MPFL reconstruction with autologous tendon graft vs. artificial grafts (FiberTape)M22.0Recurrent dislocation of patellaDRKS00015654niversitätsklinikum Hamburg-Eppendorf90
Active, not recruiting
Not Applicable
Klinische Studie zum Einfluss einer postoperativen Verabreichung von (S)-(+)-Ketamin auf das Schmerzempfinden nach großen chirurgischen Eingriffen - Ketanest®S-Schmerz-StudiePostoperatives Schmerzempfinden bei elektiven großen bauchchirurgischen Eingriffen, transabdominellen urologischen Eingriffe oder transabdominellen gynäkologischen EingriffenEUCTR2006-000714-20-ATDr. Wolfgang Jaksch150